Literature DB >> 7702575

Mechanism of anti-proliferation caused by YC-1, an indazole derivative, in cultured rat A10 vascular smooth-muscle cells.

S M Yu1, Z J Cheng, J H Guh, F Y Lee, S C Kuo.   

Abstract

An indazole derivative, YC-1, was identified in this study to be capable of reversibly and effectively inhibiting proliferation of rat A10 vascular smooth-muscle cells (VSMCs) in vitro. YC-1 (1-100 microM) dose-dependently inhibited [3H]thymidine incorporation into DNA in rat A10 VSMCs that were synchronized by serum depletion and then restimulated by addition of 10% foetal calf serum (FCS), whereas FCS-induced [3H]thymidine incorporation into rat synchronized endothelial cells was unaffected by this agent. The dose of YC-1 required to cause inhibition of FCS-induced proliferation was similar to that necessary for the formation of cellular cyclic GMP (cGMP). Guanylate cyclase activity in soluble fractions of VSMCs was activated by YC-1 (1-100 microM), whereas cGMP-specific phosphodiesterase activity was unaffected by this compound. The anti-proliferative effect of YC-1 was mimicked by 8-bromo-cGMP, a membrane-permeable cGMP analogue, and was antagonized by KT 5823 (0.2 microM), a selective inhibitor of protein kinase G. The anti-proliferative effect of YC-1 was also antagonized by Methylene Blue (50 microM), a guanylate cyclase inhibitor, and was potentiated by 3-isobutyl-1-methylxanthine (500 microM), a phosphodiesterase inhibitor. These results verified that YC-1 is a direct soluble guanylate cyclase activator in A10 VSMCs, and the anti-proliferative effect of YC-1 is mediated by cGMP. YC-1 still inhibited FCS-induced DNA synthesis even when added 10-18 h after restimulation of the serum-deprived A10 VSMCs with 10% FCS. Flow cytometry in synchronized populations revealed an acute blockage of FCS-inducible cell-cycle progression at a point in the G1/S-phase in YC-1 (100 microM)-treated cells. The inhibition of proliferation by YC-1 was demonstrated to be independent of cell damage, as documented by several criteria of cell viability. In conclusion, YC-1 reversibly and effectively inhibited the proliferation of VSMCs, suggesting that it has potential as a therapeutic agent in the prevention of vascular diseases.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7702575      PMCID: PMC1136590          DOI: 10.1042/bj3060787

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  41 in total

1.  YC-1, a novel activator of platelet guanylate cyclase.

Authors:  F N Ko; C C Wu; S C Kuo; F Y Lee; C M Teng
Journal:  Blood       Date:  1994-12-15       Impact factor: 22.113

Review 2.  Smooth muscle phenotypic changes in arterial wall homeostasis: implications for the pathogenesis of atherosclerosis.

Authors:  G R Campbell; J H Campbell
Journal:  Exp Mol Pathol       Date:  1985-04       Impact factor: 3.362

3.  [Studies on heterocyclic compounds. XXXIV. Synthesis of furo[3,2-c]pyrazole derivatives. (2). Electrophilic substitution of 1,3-diphenylfuro[3,2-c]pyrazole (author's transl)].

Authors:  S Yoshina; A Tanaka; S C Kuo
Journal:  Yakugaku Zasshi       Date:  1978-02       Impact factor: 0.302

4.  The antiproliferative effect of interferon and the mitogenic activity of growth factors are independent cell cycle events. Studies with vascular smooth muscle cells and endothelial cells.

Authors:  A D Heyns; A Eldor; I Vlodavsky; N Kaiser; R Fridman; A Panet
Journal:  Exp Cell Res       Date:  1985-12       Impact factor: 3.905

5.  Kinetics of cellular proliferation after arterial injury. I. Smooth muscle growth in the absence of endothelium.

Authors:  A W Clowes; M A Reidy; M M Clowes
Journal:  Lab Invest       Date:  1983-09       Impact factor: 5.662

6.  Prostaglandin E1 inhibits DNA synthesis in arterial smooth muscle cells stimulated with platelet-derived growth factor.

Authors:  J Nilsson; A G Olsson
Journal:  Atherosclerosis       Date:  1984-10       Impact factor: 5.162

7.  Calcium-induced release from platelet membranes of fatty acids that modulate soluble guanylate cyclase.

Authors:  R Gerzer; P Hamet; A H Ross; J A Lawson; J G Hardman
Journal:  J Pharmacol Exp Ther       Date:  1983-07       Impact factor: 4.030

8.  Inhibition of rat arterial smooth muscle cell proliferation by heparin. II. In vitro studies.

Authors:  R L Hoover; R Rosenberg; W Haering; M J Karnovsky
Journal:  Circ Res       Date:  1980-10       Impact factor: 17.367

9.  Cell cycle-dependent inhibition of human vascular smooth muscle cell proliferation by prostaglandin E1.

Authors:  C Loesberg; R van Wijk; J Zandbergen; W G van Aken; J A van Mourik; P G de Groot
Journal:  Exp Cell Res       Date:  1985-09       Impact factor: 3.905

10.  Adenosine receptor-mediated changes in cyclic AMP production and DNA synthesis in cultured arterial smooth muscle cells.

Authors:  B Jonzon; J Nilsson; B B Fredholm
Journal:  J Cell Physiol       Date:  1985-09       Impact factor: 6.384

View more
  3 in total

1.  Growth-inhibitory effect of cyclic GMP- and cyclic AMP-dependent vasodilators on rat vascular smooth muscle cells: effect on cell cycle and cyclin expression.

Authors:  N Kronemann; W A Nockher; R Busse; V B Schini-Kerth
Journal:  Br J Pharmacol       Date:  1999-01       Impact factor: 8.739

2.  Effects of the soluble guanylyl cyclase activator, YC-1, on vascular tone, cyclic GMP levels and phosphodiesterase activity.

Authors:  J Galle; U Zabel; U Hübner; A Hatzelmann; B Wagner; C Wanner; H H Schmidt
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

3.  Cyclic-GMP-dependent protein kinase inhibits the Ras/Mitogen-activated protein kinase pathway.

Authors:  M Suhasini; H Li; S M Lohmann; G R Boss; R B Pilz
Journal:  Mol Cell Biol       Date:  1998-12       Impact factor: 4.272

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.